In combination with bevacizumab, paclitaxel, and carboplatin for advanced nonsquamous NSCLC with no EGFR or ALK genomic tumor aberrationsAdvanced NSCLC whose tumors have high PD‐L1 expression (PD‐L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD‐L1 stained tumor‐infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), with no EGFR or ALK genomic tumor aberrations. This evidence concerns the gene ALK and non-small cell lung carcinoma.